Ceribell Reports Third Quarter 2024 Financial Results
CeriBell, Inc. (CBLL)
Company Research
Source: GlobeNewswire
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 & Recent Highlights Reported total revenue of $17.2 million in the third quarter of 2024, a 48% increase compared to the same period in 2023 Achieved gross margin of 87% compared to 84% for the same period in 2023 Ended the quarter with 504 total active accounts Completed initial public offering, raising approximately $188 million in net proceeds to the company Published results in Neurocritical Care, the journal of the Neurocritical Care Society, demonstrating a 4.1-day reduction in length of ICU stay and better patient outcomes with Ceribell compared to conventional EEG* Received Authority to Operate (ATO) from the U.S. Department of Veterans Affairs for Clar
Show less
Read more
Impact Snapshot
Event Time:
CBLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBLL alerts
High impacting CeriBell, Inc. news events
Weekly update
A roundup of the hottest topics
CBLL
News
- CeriBell (NASDAQ: CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $30.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Ceribell Receives Authority to Operate from the U.S. Department of Veterans AffairsGlobeNewswire
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumGlobeNewswire
- CeriBell (NASDAQ: CBLL) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- CeriBell (NASDAQ: CBLL) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
CBLL
Earnings
- 11/12/24 - Miss
CBLL
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 11/8/24 - Form SEC
- CBLL's page on the SEC website